CME in Minutes: Education in Oncology & Hematology

Please visit answersincme.com/860/100850799-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Jane Meisel, MD, FASCO. In this activity, experts in breast cancer discuss practical approaches to optimize survivorship and patient care for patients with HER2-positive metastatic breast cancer who are on first-line maintenance treatment. Upon completion of this activity, participants should be better able to: Summarize the latest evidence supporting novel first-line maintenance strategies in HR-positive, HER2-positive mBC; and Determine evidence-based practical approaches with evolving first-line maintenance treatment to optimize care for patients with HR-positive, HER2-positive mBC.

Please visit answersincme.com/KWA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Benjamin Levy, MD, FASCO. In this activity, an expert in oncology discusses the use of subcutaneous immune checkpoint inhibitors. Upon completion of this activity, participants should be better able to: Describe the rationale for subcutaneous (SC) immune checkpoint inhibitor (ICI) administration in the context of standard care with intravenous (IV) formulations in patients with advanced solid tumors; Review the evidence for SC formulations of ICIs compared with IV formulations in patients with advanced solid tumors; and Propose patient-centered strategies for enhancing care with SC administration of ICIs in patients with advanced solid tumors.

Please visit answersincme.com/860/100850799-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Otto Metzger, MD. In this activity, experts in breast cancer discuss the clinical implications of recent data on first-line maintenance strategies in HER2-positive metastatic breast cancer. Upon completion of this activity, participants should be better able to: Summarize the latest evidence supporting novel first-line maintenance strategies in HR-positive, HER2-positive mBC; and Determine evidence-based practical approaches with evolving first-line maintenance treatment to optimize care for patients with HR-positive, HER2-positive mBC.

Please visit answersincme.com/860/101393625-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Yohann Loriot, MD, PhD and Andrea Necchi, MD. In this activity, experts in genitourinary cancers examine evidence-based strategies for integrating HER2 biomarker testing and HER2-directed antibody-drug conjugates into personalized, multidisciplinary care for advanced bladder cancer. Upon completion of this activity, participants should be better able to: Apply current guidelines to incorporate biomarker testing into treatment pathways for advanced bladder cancer; Evaluate emerging data on HER2-directed antibody-drug conjugates to guide the management of advanced bladder cancer; and Formulate multidisciplinary treatment plans to support personalized care for patients with HER2-positive advanced bladder cancer.

Please visit answersincme.com/HAC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Kohei Shitara, MD, PhD. In this activity, an expert in gastrointestinal oncology discusses the latest data for the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma. Upon completion of this activity, participants should be better able to: Discuss the latest efficacy and safety data for HER2-directed antibody-drug conjugates in the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma; and Translate the latest data for the treatment of gastric and GEJ adenocarcinoma within the context of the current treatment landscape.

Please visit answersincme.com/860/100850799-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Sara A. Hurvitz, MD, FACP. In this activity, experts in breast cancer discuss the evolving standard-of-care and emerging first-line maintenance strategies in HER2-positive metastatic breast cancer. Upon completion of this activity, participants should be better able to: Review the rationale for expanding the first-line maintenance therapy options for patients with HR-positive, HER2-positive mBC; and Summarize the latest evidence supporting novel first-line maintenance strategies in HR-positive, HER2-positive mBC.

Please visit answersincme.com/DZU860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michelle Jacobson, MD, MHSc, FRCSC, MSCP; Nadia Harbeck, MD, PhD; and Renate Haidinger. In this activity, experts in breast cancer and menopause discuss the burden of vasomotor symptoms (VMS) due to breast cancer treatment and the emerging role of neurokinin (NK) receptor antagonists in alleviating these symptoms in practice, with insights from a patient advocate. Upon completion of this activity, participants should be better able to: Recognize VMS as a consequence of breast cancer treatment; Outline the clinical rationale for novel therapeutic approaches to manage VMS associated with breast cancer treatment; Evaluate the efficacy and safety of NK receptor antagonists for breast cancer treatment–associated VMS; and Implement patient-centered clinical approaches to elevate the quality of life of patients experiencing breast cancer–associated VMS.

Please visit answersincme.com/860/120773-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alex Spira, MD, PhD, FASCO; and Kathryn C. Arbour, MD. In this activity "In this activity, experts in oncology discuss the evolving role of RAS(ON) inhibitors in shaping future treatment strategies for patients with KRAS-mutated non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Identify areas of unmet need in KRAS-mutant NSCLC across diverse KRAS variants in pretreated advanced settings; Describe the rationale for the use of RAS(ON) inhibitors for patients with KRAS-mutated NSCLC, based on evidence; and Assess how RAS(ON) inhibitors may be optimally used in clinical practice as they become available.

Please visit answersincme.com/CZS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Giuseppe Curigliano, MD, PhD. In this activity, an expert in oncology discusses the differentiation of patients with HER2-low/ultralow/negative advanced breast cancer and treatment with antibody-drug conjugates. Upon completion of this activity, participants should be better able to: Differentiate HER2-low, -ultralow, and -negative advanced breast cancer; Identify patients with HER2-low and -ultralow advanced breast cancer who would benefit from treatment with antibody-drug conjugates; and Apply evidence-based strategies to connect testing to treatment in patients with HER2-low or -ultralow advanced breast cancer.

Please visit answersincme.com/RCG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Raymond Osarogiagbon, MD, MBBS, FACP, FASCO; and Michael Gieske, MD. In this activity, experts in lung cancer discuss practical strategies for lung cancer screening. Upon completion of this activity, participants should be better able to: Recognize barriers to achieving lung cancer screening for eligible patients; Identify patients at high risk of lung cancer who are eligible for screening; and Outline practical, patient-centered strategies to appropriately integrate lung cancer screening into routine practice.